glycoprotein substrate

By Targets:	P-glycoprotein (11) AMPK (1) Antibiotic (3) Apoptosis (2) Bacterial (3) BCRP (2) Chloride Channel (2) Cytochrome P450 (5) Endogenous Metabolite (5) HIV (5) HIV Protease (5) iGluR (1) Isotope-Labeled Compounds (3) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) NF-κB (1) Opioid Receptor (1) Parasite (4) PPAR (1) SARS-CoV (5)
By Research Areas:	Cancer (10) Infection (10) Inflammation/Immunology (1) Metabolic Disease (3) Neurological Disease (2)

Targets Recommended: Glycoprotein VI P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107212

Selamectin	Parasite Chloride Channel P-glycoprotein Bacterial	Infection
Selamectin, a semi-synthetic macrocyclic lactone, is a potent parasiticide and anthelminthic. Selamectin activates glutamate-gated chloride channels in neurons and pharyngeal muscles to prevent heartworm, *Lymphatic filariae, and nematode* infection. Selamectin is also a potent *P-glycoprotein* substrate and a *P-glycoprotein* inhibitor with an IC₅₀ of 120 nM .

HY-A0279A

Pristinamycin IA 1 Publications Verification Mikamycin B; Mikamycin IA	Bacterial Antibiotic	Infection
Pristinamycin IA (Mikamycin B) is a cycle-peptidic macrolactone antibiotic. Pristinamycin IA is a substrate of *P-glycoprotein* and inhibits its function. Pristinamycin IA is active against StaphyloEoccus and Srreptococcus .

HY-16191

ELR510444 1 Publications Verification	Microtubule/Tubulin Apoptosis	Cancer
ELR510444 is a novel microtubule disruptor; inhibits MDA-MB-231 cell proliferation with IC50 of 30.9 nM; not a substrate for the P-glycoprotein drug transporter and retains activity in βIII-tubulin-overexpressing cell lines.

HY-107212R

Selamectin (Standard)	Parasite Chloride Channel P-glycoprotein Bacterial	Infection
Selamectin (Standard) is the analytical standard of Selamectin. This product is intended for research and analytical applications. Selamectin, a semi-synthetic macrocyclic lactone, is a potent parasiticide and anthelminthic. Selamectin activates glutamate-gated chloride channels in neurons and pharyngeal muscles to prevent heartworm, *Lymphatic filariae, and nematode* infection. Selamectin is also a potent *P-glycoprotein* substrate and a *P-glycoprotein* inhibitor with an IC₅₀ of 120 nM .

HY-128038

N-Desmethyl-loperamide	Opioid Receptor	Neurological Disease
N-Desmethyl-loperamide is a major metabolite of loperamide, a drug that selectively activates peripheral μopioid receptors with a K_i value of 0.16 nM. N-Desmethyl-loperamide is a substrate of the ATP-dependent efflux transporter P-glycoprotein .

HY-N3197

Neostenine (+)-Neostenine	P-glycoprotein	Cancer
Neostenine is a stenine-type Stemona alkaloid, with antitussive activity. Neostenine is also a substrate of *P-glycoprotein* with high absorptive permeability in Caco-2 monolayer model. Neostenine also shows oral activity for intestinal application .

HY-137261

UDP-β-D-glucose disodium	Others	Metabolic Disease
UDP-β-D-glucose disodium is a the stereoisomer of UDP-α-D-glucose. UDP-β-D-glucose disodium is an oligosaccharide that can be used to synthesize glycoproteins and glycolipids. UDP-β-D-glucose disodium can be used as a substrate .

HY-B0777

Moxidectin 1 Publications Verification CL301423	Antibiotic BCRP P-glycoprotein Parasite	Infection
Moxidectin (CL301423) is an orally active macrolide (ML) anthelmintic for the prevention and control of heartworms and roundworms. Moxidectin is also a substrate of BCRP and P-glycoprotein (P-gp) in vivo, and is secreted into breast milk and effluxed from the host and parasite mediated by Bcrp1 and P-gp. This may be related to the presence of chemical residues in milk .

HY-P2869A

β1-3 Galactosidase	Others	Metabolic Disease
β1-3 Galactosidase is a highly specific exoglycosidase that catalyzes the hydrolysis of terminal β1-3-linked galactose from oligosaccharides and glycoprotein substrates, at a much lower rate, β1-6 linked galactose residues from oligosaccharides .

HY-16397

Phenformin Phenethylbiguanide	Mitochondrial Metabolism AMPK Apoptosis	Metabolic Disease Cancer
Phenformin (1-phenethylbiguanide) is an orally active antidiabetic and anticancer agent. Phenformin has an incidence of associated lactic acidosis. Phenformin acts through acting AMPK activation and blocking mTOR pathway. Phenformin is also a substrate of P-glycoprotein (P-gp), and an OXPHOS inhibitor. Phenformin induces cancer cell apoptosis .

HY-17367

Atazanavir Maximum Cited Publications 11 Publications Verification BMS-232632	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of *P-glycoprotein* (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 3.49 μM .

HY-17367A

Atazanavir sulfate Maximum Cited Publications 11 Publications Verification BMS-232632 sulfate	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of *P-glycoprotein* (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 3.49 μM .

HY-W001601

Budipine	iGluR	Neurological Disease
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .

HY-B0777R

Moxidectin (Standard) CL301423 (Standard)	Antibiotic BCRP P-glycoprotein Parasite	Infection
Moxidectin (Standard) is the analytical standard of Moxidectin. This product is intended for research and analytical applications. Moxidectin (CL301423) is an orally active macrolide (ML) anthelmintic for the prevention and control of heartworms and roundworms. Moxidectin is also a substrate of BCRP and P-glycoprotein (P-gp) in vivo, and is secreted into breast milk and effluxed from the host and parasite mediated by Bcrp1 and P-gp. This may be related to the presence of chemical residues in milk .

HY-N2453

Convallatoxin	PPAR NF-κB P-glycoprotein	Inflammation/Immunology Cancer
Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .

HY-17367S3

Atazanavir-d5	Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S2

Atazanavir-d9 BMS-232632-d₉	Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S4

Atazanavir-d6 BMS-232632-d₆	Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

Cat. No.	Product Name	Type

HY-107903

Thyroglobulin Thyroglobulin from bovine	Native Proteins
Thyroglobulin is a 660 kDa, dimeric glycoprotein produced by the follicular cells of the thyroid and used entirely within the thyroid gland. Thyroglobulin acts as a substrate for the synthesis of the thyroid hormones thyroxine (T4) and triiodothyronine (T3), as well as the storage of the inactive forms of thyroid hormone and iodine within the follicular lumen of a thyroid follicle .

HY-E70054

beta-1,3-Galactosyltransferase (WbgO) CgtB	Biochemical Assay Reagents
beta-1,3-Galactosyltransferase (WbgO) (CgtB) acts on N-glycan substrates. beta-1,3-Galactosyltransferase (WbgO) catalyzes the formation of type 1 chains on oligosaccharide, glycopeptide, and glycoprotein substrates, including itself .

HY-P3008

Submandibular mucin

Native Proteins

Submandibular mucin is a high molecular weight glycoprotein that is used as a substrate for the viral enzyme neuraminidase .

Submandibular mucin	Native Proteins
Submandibular mucin is a high molecular weight glycoprotein that is used as a substrate for the viral enzyme neuraminidase .

HY-E70039

alpha-2-3,6,8-Sialidosidase (SpNanA)	Biochemical Assay Reagents
alpha-2-3,6,8-Sialidosidase (SpNanA) catalyses hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates .

Cat. No.	Product Name	Target	Research Area

HY-P3008

Submandibular mucin

Peptides Others

Submandibular mucin is a high molecular weight glycoprotein that is used as a substrate for the viral enzyme neuraminidase .

Submandibular mucin	Peptides	Others
Submandibular mucin is a high molecular weight glycoprotein that is used as a substrate for the viral enzyme neuraminidase .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-A0279A

Pristinamycin IA 1 Publications Verification Mikamycin B; Mikamycin IA	Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Cyclopeptides Source classification Other Diseases Antibacterial Disease Research Disease Research Fields	Bacterial Antibiotic
Pristinamycin IA (Mikamycin B) is a cycle-peptidic macrolactone antibiotic. Pristinamycin IA is a substrate of *P-glycoprotein* and inhibits its function. Pristinamycin IA is active against StaphyloEoccus and Srreptococcus .

HY-17367

Atazanavir Maximum Cited Publications 11 Publications Verification BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of *P-glycoprotein* (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 3.49 μM .

HY-17367A

Atazanavir sulfate Maximum Cited Publications 11 Publications Verification BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of *P-glycoprotein* (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 3.49 μM .

HY-N2453

Convallatoxin	Triterpenes Structural Classification Classification of Application Fields Terpenoids Ranunculaceae Adonis amurensis Regel et Radde Plants Inflammation/Immunology Disease Research Fields	PPAR NF-κB P-glycoprotein
Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .

HY-N3197

Neostenine (+)-Neostenine	Structural Classification Alkaloids Pyrrole Alkaloids Stemonaceae Other Alkaloids Source classification Plants Stemona sesslifolia	P-glycoprotein
Neostenine is a stenine-type Stemona alkaloid, with antitussive activity. Neostenine is also a substrate of *P-glycoprotein* with high absorptive permeability in Caco-2 monolayer model. Neostenine also shows oral activity for intestinal application .

Cat. No.	Product Name	Chemical Structure

HY-17367S4

Atazanavir-d6
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S3

Atazanavir-d5
Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S2

Atazanavir-d9
Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

glycoprotein substrate

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products